Seaport and Hemab target $180m IPOs as biotech listings accumulate
Hemostemix Raises $784,000 to Advance Stem Cell Therapy Commercialization
Hemostemix Leadership Attending Abundance360 Summit | HMTXF Stock News
Psychedelic biotechs are moving towards Phase 3 with five companies advancing CNS treatments for depression and anxiety.
Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML